ImmunoGen, Inc.·4

Jan 3, 5:17 PM ET

VASCONCELLES MICHAEL 4

4 · ImmunoGen, Inc. · Filed Jan 3, 2023

Insider Transaction Report

Form 4
Period: 2022-12-29
VASCONCELLES MICHAEL
EVP R&D & MEDICAL AFFAIRS
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-12-29+960,000960,000 total
    Exercise: $5.16Exp: 2032-12-29Common Stock (960,000 underlying)
Footnotes (1)
  • [F1]These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.

Documents

1 file
  • 4
    form4-01032023_100157.xmlPrimary